$9.97
0.66% today
Nasdaq, Apr 01, 06:19 pm CET
ISIN
US15687V1098
Symbol
CERT

Certara Stock price

$9.90
-2.08 17.36% 1M
-1.81 15.46% 6M
-0.75 7.04% YTD
-8.10 45.00% 1Y
-11.58 53.91% 3Y
-28.18 74.00% 5Y
-28.18 74.00% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.01 0.10%
ISIN
US15687V1098
Symbol
CERT

Key metrics

Market capitalization $1.59b
Enterprise Value $1.73b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 21.90
EV/Sales (TTM) EV/Sales 4.48
P/S ratio (TTM) P/S ratio 4.14
P/B ratio (TTM) P/B ratio 1.51
Revenue growth (TTM) Revenue growth 8.70%
Revenue (TTM) Revenue $385.15m
EBIT (operating result TTM) EBIT $13.00m
Free Cash Flow (TTM) Free Cash Flow $78.84m
Cash position $179.18m
EPS (TTM) EPS $-0.08
P/E forward 495.00
P/S forward 3.79
EV/Sales forward 4.10
Short interest 4.88%
Show more

Is Certara a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Certara Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Certara forecast:

5x Buy
42%
7x Hold
58%

Analyst Opinions

12 Analysts have issued a Certara forecast:

Buy
42%
Hold
58%

Financial data from Certara

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
385 385
9% 9%
100%
- Direct Costs 208 208
12% 12%
54%
177 177
6% 6%
46%
- Selling and Administrative Expenses 59 59
7% 7%
15%
- Research and Development Expense 37 37
9% 9%
10%
81 81
16% 16%
21%
- Depreciation and Amortization 68 68
21% 21%
18%
EBIT (Operating Income) EBIT 13 13
7% 7%
3%
Net Profit -12 -12
78% 78%
-3%

In millions USD.

Don't miss a Thing! We will send you all news about Certara directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Certara Stock News

Neutral
GlobeNewsWire
about 5 hours ago
RADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has released a new version of the Simcyp™ Simulator for physiologically-based pharmacokinetic (PBPK) modeling.
Neutral
GlobeNewsWire
27 days ago
RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D.
Neutral
Seeking Alpha
about one month ago
Certara, Inc. (NASDAQ:CERT ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Jeff Garro - Stephens Inc. Michael Cherny - Leerink Partners Christine Rains - William Blair David Windley - Jefferi...
More Certara News

Company Profile

Certara, Inc. engages in the provision of software and technology enables services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017 and is headquartered in Princeton, NJ.

Head office United States
CEO William Feehery
Employees 1,546
Founded 2008
Website www.certara.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today